Arcturus Therapeutics Holdings Inc. is a clinical-stage biotechnology company that specializes in the development of messenger RNA (mRNA) medicines and vaccines. Headquartered in San Diego, California, the company leverages two core proprietary technology platforms: STARR, a self-amplifying mRNA technology designed to produce prolonged protein expression at lower doses, and LUNAR, a lipid-mediated delivery system that safely and effectively delivers RNA to target cells.
The company's pipeline is divided into two main areas: rare diseases and infectious disease vaccines. In the rare disease space, Arcturus is advancing ARCT-032 (LUNAR-CF), an inhaled mRNA therapeutic candidate for cystic fibrosis, and ARCT-810 (LUNAR-OTC), an mRNA therapeutic for ornithine transcarbamylase (OTC) deficiency. In the infectious disease segment, the company has developed KOSTAIVE, a self-amplifying mRNA COVID-19 vaccine that received its first historic approval in Japan, and is advancing vaccine candidates for seasonal and pandemic influenza.
Arcturus generates revenue primarily through collaboration payments, licensing fees, research support, and grants. A significant portion of its revenue comes from a global collaboration with CSL Seqirus for the development and commercialization of its mRNA vaccines, which has accounted for the vast majority of its revenue in recent fiscal years. Additionally, the company receives funding from the U.S. Biomedical Advanced Research and Development Authority (BARDA) for pandemic flu vaccine development. Arcturus operates globally through its partnerships and a joint venture in Japan, ARCALIS, which focuses on the manufacturing of mRNA vaccines and therapeutics.
